SAM
SMMT icon

Smartleaf Asset Management’s Summit Therapeutics SMMT Stock Holding History

Smartleaf Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.48K Hold
662
– – ﹤0.01% 2392
2026
Q1 		$11.2K Buy
662
+27
+4% +$437 ﹤0.01% 2267
2025
Q4 		$11.1K Buy
635
+64
+11% +$1.2K ﹤0.01% 2350
2025
Q3 		$12.1K Buy
571
+566
+11,320% +$13.7K ﹤0.01% 2030
2025
Q2 		$103 Buy
+5
New +$114 ﹤0.01% 2690

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Smartleaf Asset Management's SMMT Position: Q2 2026 in Review

Smartleaf Asset Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 662 shares worth $9.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Smartleaf Asset Management first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $12.1K in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Smartleaf Asset Management held 662 shares of Summit Therapeutics worth $9.48K as of Q2 2026.
  • Smartleaf Asset Management left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2392 holding.
  • Smartleaf Asset Management first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Smartleaf Asset Management's Summit Therapeutics position peaked at $12.1K in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.